Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More
STERLING BIOTECH | DR. REDDYS LAB | STERLING BIOTECH/ DR. REDDYS LAB |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -0.4 | 37.1 | - | View Chart |
P/BV | x | 0.0 | 5.1 | 0.3% | View Chart |
Dividend Yield | % | 0.0 | 0.5 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
STERLING BIOTECH Dec-13 |
DR. REDDYS LAB Mar-20 |
STERLING BIOTECH/ DR. REDDYS LAB |
5-Yr Chart Click to enlarge
|
||
High | Rs | 11 | 3,363 | 0.3% | |
Low | Rs | 3 | 2,352 | 0.1% | |
Sales per share (Unadj.) | Rs | 26.8 | 1,054.2 | 2.5% | |
Earnings per share (Unadj.) | Rs | -15.0 | 121.9 | -12.3% | |
Cash flow per share (Unadj.) | Rs | -5.5 | 190.2 | -2.9% | |
Dividends per share (Unadj.) | Rs | 0 | 25.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.9 | 0.0% | |
Book value per share (Unadj.) | Rs | 54.9 | 938.7 | 5.8% | |
Shares outstanding (eoy) | m | 267.87 | 166.17 | 161.2% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 0.3 | 2.7 | 9.6% | |
Avg P/E ratio | x | -0.5 | 23.4 | -2.0% | |
P/CF ratio (eoy) | x | -1.3 | 15.0 | -8.5% | |
Price / Book Value ratio | x | 0.1 | 3.0 | 4.2% | |
Dividend payout | % | 0 | 20.5 | 0.0% | |
Avg Mkt Cap | Rs m | 1,862 | 474,831 | 0.4% | |
No. of employees | `000 | 1.4 | 21.7 | 6.3% | |
Total wages/salary | Rs m | 547 | 33,802 | 1.6% | |
Avg. sales/employee | Rs Th | 5,303.3 | 8,091.0 | 65.5% | |
Avg. wages/employee | Rs Th | 403.8 | 1,561.3 | 25.9% | |
Avg. net profit/employee | Rs Th | -2,959.0 | 935.8 | -316.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 7,181 | 175,170 | 4.1% | |
Other income | Rs m | 43 | 6,206 | 0.7% | |
Total revenues | Rs m | 7,223 | 181,376 | 4.0% | |
Gross profit | Rs m | 947 | 24,421 | 3.9% | |
Depreciation | Rs m | 2,543 | 11,348 | 22.4% | |
Interest | Rs m | 4,377 | 983 | 445.3% | |
Profit before tax | Rs m | -5,931 | 18,296 | -32.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 561 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -1,924 | -1,403 | 137.2% | |
Profit after tax | Rs m | -4,007 | 20,260 | -19.8% | |
Gross profit margin | % | 13.2 | 13.9 | 94.6% | |
Effective tax rate | % | 32.4 | -7.7 | -423.1% | |
Net profit margin | % | -55.8 | 11.6 | -482.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 14,335 | 125,991 | 11.4% | |
Current liabilities | Rs m | 49,809 | 72,141 | 69.0% | |
Net working cap to sales | % | -494.0 | 30.7 | -1,607.0% | |
Current ratio | x | 0.3 | 1.7 | 16.5% | |
Inventory Days | Days | 403 | 73 | 552.0% | |
Debtors Days | Days | 171 | 105 | 162.9% | |
Net fixed assets | Rs m | 55,432 | 83,854 | 66.1% | |
Share capital | Rs m | 268 | 831 | 32.2% | |
"Free" reserves | Rs m | 13,935 | 155,157 | 9.0% | |
Net worth | Rs m | 14,701 | 155,988 | 9.4% | |
Long term debt | Rs m | 9,478 | 1,304 | 726.8% | |
Total assets | Rs m | 73,988 | 232,253 | 31.9% | |
Interest coverage | x | -0.4 | 19.6 | -1.8% | |
Debt to equity ratio | x | 0.6 | 0 | 7,712.0% | |
Sales to assets ratio | x | 0.1 | 0.8 | 12.9% | |
Return on assets | % | 0.5 | 9.1 | 5.5% | |
Return on equity | % | -27.3 | 13.0 | -209.8% | |
Return on capital | % | -6.4 | 12.6 | -50.9% | |
Exports to sales | % | 25.9 | 0 | - | |
Imports to sales | % | 0.2 | 0 | - | |
Exports (fob) | Rs m | 1,860 | NA | - | |
Imports (cif) | Rs m | 12 | NA | - | |
Fx inflow | Rs m | 1,860 | 84,193 | 2.2% | |
Fx outflow | Rs m | 25 | 39,616 | 0.1% | |
Net fx | Rs m | 1,835 | 44,577 | 4.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,719 | 29,841 | 5.8% | |
From Investments | Rs m | -3,148 | -4,923 | 63.9% | |
From Financial Activity | Rs m | 1,426 | -25,159 | -5.7% | |
Net Cashflow | Rs m | -3 | -266 | 1.3% |
Indian Promoters | % | 33.9 | 25.5 | 132.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 5.4 | - | |
FIIs | % | 9.9 | 35.3 | 28.0% | |
ADR/GDR | % | 16.9 | 18.5 | 91.4% | |
Free float | % | 39.3 | 15.3 | 256.9% | |
Shareholders | 21,482 | 75,885 | 28.3% | ||
Pledged promoter(s) holding | % | 55.9 | 0.0 | - |
Compare STERLING BIOTECH With: ELDER PHARMA FDC SUN PHARMA DISHMAN PHARMA TTK HEALTHCARE
Compare STERLING BIOTECH With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.
Ajit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
What should you do if the market falls? In this video, I'll tell you what I will do.
A favourable demand supply scenario makes a strong case for real estate prices.
Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market
More